Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Good
|
New words:
Agent, aka, Armistice, astute, Avenue, Barnard, Bio, BioSpectrum, biotechnology, Boardroom, Boyd, BTI, Challenge, chapter, Chemistry, Client, Club, CMC, complex, computed, conclusive, concurrent, confirmation, correction, counsel, Crain, deemed, dispose, Door, EBET, Education, Entera, error, Euromoney, excluded, Floor, Gilda, greater, Green, Hine, holder, human, IML, Immune, inability, INF, Interferon, internationally, inventory, JD, LMG, longer, Madison, matter, Metro, myriad, Nevada, Notable, owed, partner, Placement, Presidential, Program, Psychology, Ready, recipient, recognized, recovery, Red, return, RSU, Schedule, settlement, Spinal, Star, Steven, taught, Thompson, transferred, valuable, virtue, Waldemar, York
Filing tables
Filing exhibits
CNSP similar filings
Filing view
External links
EXHIBIT 31.1
CERTIFICATION BY OFFICER
I, John Climaco, certify that:
1. | I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A for the year ended December 31, 2022 of CNS Pharmaceuticals, Inc.; and |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
Date: May 1, 2023 | By: | /s/ John Climaco |
John Climaco | ||
Chief Executive Officer and President |